The role of PET in lymphoma.

Malignant lymphomas are a heterogeneous group of diseases whose treatment and prognosis depend on accurate staging and evaluation of histologic features. The conventional imaging procedure is CT; however, nuclear medicine imaging has also had a prominent role. Single-photon imaging with 67Ga-citrate has been widely used for lymphomas. PET with 18F-FDG has gained a role in the staging and follow-up of lymphomas, largely replacing gallium as the nuclear medicine study of choice. 18F-FDG PET has proved useful in the staging and follow-up of Hodgkin's disease and non-Hodgkin's lymphoma (especially more aggressive types), and the widespread use of PET/CT has also increased the sensitivity and specificity. Its usefulness for the staging of slow-growing lymphomas has not been established. After the basics of staging and classification of lymphomas have been outlined, this article will review the role of 18F-FDG PET in the management of patients with lymphoma. PET tracers other than (18)F-FDG, such as positron-emitting isotopes of gallium and the cellular proliferation marker 18F-3'-deoxy-3'-fluorothymidine, will be discussed and future directions for PET in lymphoma proposed.

[1]  Z. Miltényi,et al.  Mediastinal Bulky Tumour in Hodgkin’s Disease and Prognostic Value of Positron Emission Tomography in the Evaluation of Post-Treatment Residual Masses , 2004, Acta Haematologica.

[2]  Thomas Beyer,et al.  FDG-PET/CT in re-staging of patients with lymphoma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[4]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[5]  G. Ayers,et al.  Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Någren,et al.  Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  J Kotzerke,et al.  Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. , 1997, Radiology.

[8]  O. Israel,et al.  The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging. , 1997, Seminars in nuclear medicine.

[9]  B. Beuthien-Baumann,et al.  Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma , 2004, British Journal of Cancer.

[10]  U. Cremerius,et al.  Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. , 1998, Nuclear medicine communications.

[11]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Avril,et al.  Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients with Prior Myeloablative Chemotherapy , 2005, Clinical Cancer Research.

[14]  S. Reske,et al.  [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study. , 2004, Cancer biotherapy & radiopharmaceuticals.

[15]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[16]  S. Holm,et al.  PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Thomas F Hany,et al.  Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? , 2004, Radiology.

[18]  Michael E. Phelps,et al.  Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma , 2001 .

[19]  Emmanuel Itti,et al.  [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.

[20]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  R. Wahl,et al.  Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Sven N Reske,et al.  3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.

[23]  B. Glimelius,et al.  Predicting malignancy grade with PET in non-Hodgkin's lymphoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  J. Winter,et al.  Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. , 2006, Haematologica.

[25]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[26]  B. Gross,et al.  Upper abdominal lymph nodes: criteria for normal size determined with CT. , 1991, Radiology.

[27]  M Schwaiger,et al.  Reproducibility of metabolic measurements in malignant tumors using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[29]  S. Larson,et al.  Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. , 1980, Journal of the National Cancer Institute.

[30]  S. Ben-Haim,et al.  Residual mass and negative gallium scintigraphy in treated lymphoma. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[32]  Luca Nassi,et al.  18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. , 2005, Oncology reports.

[33]  R. Hicks,et al.  Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. , 2003, Clinical lymphoma.

[34]  Mithat Gonen,et al.  Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  S. Larson,et al.  The role of transferrins in gallium uptake. , 1981, International journal of nuclear medicine and biology.

[36]  D. Podoloff,et al.  Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  J. Connors,et al.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Canellos,et al.  High-dose gallium imaging in lymphoma. , 1983, The American journal of medicine.

[39]  R. Wahl,et al.  Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  T. Beyer,et al.  Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  M. Czuczman,et al.  Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. D. Van den Abbeele,et al.  FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients with de novo Hodgkin Lymphoma: A Blinded Comparison , 2004, Leukemia & lymphoma.

[43]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[44]  Y. Erdi,et al.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Minoshima,et al.  The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  E. Yoshikawa,et al.  Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[47]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[48]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[49]  A. Buck,et al.  Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[50]  M. Baccarani,et al.  Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients , 2004, British Journal of Cancer.

[51]  M. O'Doherty,et al.  FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  N. Tamaki,et al.  18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma. , 2004, Annals of nuclear medicine.

[53]  H. Minn,et al.  Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. , 1995, Blood.

[54]  A. Zelenetz,et al.  Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. , 2004, Blood.

[55]  Y. Erdi,et al.  Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 23: 4643-4651 , 2005 .

[56]  Paul Kinahan,et al.  A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[57]  S. Larson,et al.  New strategies in radioimmunotherapy for lymphoma , 2003, Current oncology reports.

[58]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  S. Reske,et al.  18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  D. Weisenburger,et al.  Lymphomatous polyposis. A neoplasm of either follicular mantle or germinal center cell origin. , 1996, The American journal of surgical pathology.

[61]  H. Eich,et al.  CT and MR imaging in Hodgkin's disease – present and future , 2005, European journal of haematology. Supplementum.

[62]  S. Hain,et al.  18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT , 2000, Leukemia & lymphoma.

[63]  S M Bakheet,et al.  Benign causes of 18-FDG uptake on whole body imaging. , 1998, Seminars in nuclear medicine.

[64]  Piotr J Slomka,et al.  Software Approach to Merging Molecular with Anatomic Information , 2004 .

[65]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[66]  Paul Kinahan,et al.  Attenuation correction for a combined 3D PET/CT scanner. , 1998, Medical physics.

[67]  F L Bookstein,et al.  Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. , 1985, AJR. American journal of roentgenology.

[68]  J. Leonard,et al.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[69]  A. Alavi,et al.  Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging. , 2003, Clinical Nuclear Medicine.

[70]  R. Hustinx,et al.  Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  Wolfgang A Weber,et al.  Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.